Sector ratings Genmab A/S

Equities

Market Closed - Nasdaq Copenhagen Other stock markets 16:20:00 06/03/2026 GMT			5-day change	1st Jan Change
1,728.50 ^DKK	-2.62%		-6.49%	-14.73%

03-06	UBS Lowers Price Target for Genmab to 2,600 Danish Kroner (from 2,750), Reiterates Buy	FW
03-06	Nordic Stocks in North America - Autoliv Drops 0.4 Percent	FW

Sector:

Location:

X axis:

Main competitors

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Capi.($)	Investor	ESG MSCI	Fundamentals	Financial revisions	Global Valuation	Visibility	Consensus
GENMAB A/S	16.5B		AA
ARGENX SE	44.16B		AA
WUXI APPTEC CO., LTD.	40.5B		AAA
INSMED INCORPORATED	30.21B	-	BBB	-		-
BIONTECH SE	25.47B	-	-	-		-
WUXI BIOLOGICS (CAYMAN) INC.	19.22B		AAA
AKESO, INC.	12.64B		B			-
SUMMIT THERAPEUTICS INC.	11.72B	-	-	-		-
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	11.51B	-	A	-		-
EXELIXIS, INC.	10.79B		BB
MADRIGAL PHARMACEUTICALS, INC.	9.93B	-	B	-		-
SAMSUNG EPIS HOLDINGS CO., LTD.	9.11B	-	-	-		-	-
IMMUNITYBIO, INC.	8.91B	-	B	-		-
ARROWHEAD PHARMACEUTICALS, INC.	8.38B	-	BBB	-		-
VAXCYTE, INC.	8.53B	-	BBB	-		-
CEREVEL THERAPEUTICS HOLDINGS, INC.	8.19B	-	-	-	-	-	-	-
PHARMAESSENTIA CORPORATION	8.14B		AA
NUVALENT, INC.	7.82B	-	CCC	-		-
CYTOKINETICS, INCORPORATED	7.44B	-	AA	-		-
MERUS N.V.	6.83B	-	BBB	-		-	-
Average	15.3B		A
Weighted average by Cap.			A